Prospective comparison of ¹⁸ F-FDG PET/MRI and ¹⁸ F-FDG PET/CT for thoracic staging of non-small cell lung cancer.

Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE

Original Publication: Berlin : Springer-Verlag Berlin, 2002-

Fluorodeoxyglucose F18* ; Magnetic Resonance Imaging* ; Positron Emission Tomography Computed Tomography*; Carcinoma, Non-Small-Cell Lung/*diagnostic imaging ; Carcinoma, Non-Small-Cell Lung/*pathology ; Lung Neoplasms/*diagnostic imaging ; Lung Neoplasms/*pathology; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Prospective Studies ; Thorax

Objectives: To compare the diagnostic performance of ¹⁸ F-FDG PET/MRI and ¹⁸ F-FDG PET/CT for primary and locoregional lymph node staging in non-small cell lung cancer (NSCLC).
Methods: In this prospective study, a total of 84 patients (51 men, 33 women, mean age 62.5 ± 9.1 years) with histopathologically confirmed NSCLC underwent ¹⁸ F-FDG PET/CT followed by ¹⁸ F-FDG PET/MRI in a single injection protocol. Two readers independently assessed T and N staging in separate sessions according to the seventh edition of the American Joint Committee on Cancer staging manual for ¹⁸ F-FDG PET/CT and ¹⁸ F-FDG PET/MRI, respectively. Histopathology as a reference standard was available for N staging in all 84 patients and for T staging in 39 patients. Differences in staging accuracy were assessed by McNemars chi ² test. The maximum standardized uptake value (SUV max ) and longitudinal diameters of primary tumors were correlated using Pearson's coefficients.
Results: T stage was categorized concordantly in ¹⁸ F-FDG PET/MRI and ¹⁸ F-FDG PET/CT in 38 of 39 (97.4%) patients. Herein, ¹⁸ F-FDG PET/CT and ¹⁸ F-FDG PET/MRI correctly determined the T stage in 92.3 and 89.7% of patients, respectively. N stage was categorized concordantly in 83 of 84 patients (98.8%). ¹⁸ F-FDG PET/CT correctly determined the N stage in 78 of 84 patients (92.9%), while ¹⁸ F-FDG PET/MRI correctly determined the N stage in 77 of 84 patients (91.7%). Differences between ¹⁸ F-FDG PET/CT and ¹⁸ F-FDG PET/MRI in T and N staging accuracy were not statistically significant (p > 0.5, each). Tumor size and SUV max measurements derived from both imaging modalities exhibited excellent correlation (r = 0.963 and r = 0.901, respectively).
Conclusion: ¹⁸ F-FDG PET/MRI and ¹⁸ F-FDG PET/CT show an equivalently high diagnostic performance for T and N staging in patients suffering from NSCLC.

Comment in: Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):522-523. (PMID: 30377737)

J Magn Reson Imaging. 2015 Aug;42(2):247-60. (PMID: 25365936)
Eur J Cardiothorac Surg. 2014 May;45(5):787-98. (PMID: 24578407)
J Nucl Med. 2016 Mar;57(3):420-30. (PMID: 26742709)
Eur Radiol. 2012 Dec;22(12):2859-67. (PMID: 22772365)
Clin Lung Cancer. 2012 Mar;13(2):81-9. (PMID: 22056226)
Invest Radiol. 2016 Oct;51(10):624-34. (PMID: 27175550)
Radiology. 2005 Sep;236(3):1011-9. (PMID: 16014441)
Eur J Radiol. 2014 Aug;83(8):1301-2. (PMID: 24917223)
Insights Imaging. 2012 Aug;3(4):355-71. (PMID: 22695944)
J Nucl Med. 2012 Aug;53(8):1244-52. (PMID: 22782313)
Mol Imaging Biol. 2013 Dec;15(6):776-85. (PMID: 23632951)
Eur J Radiol. 2000 Jun;34(3):196-207. (PMID: 10927161)
J Cardiothorac Surg. 2013 Apr 16;8:94. (PMID: 23591054)
J Nucl Med. 2016 Jan;57(1):21-6. (PMID: 26471696)
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21. (PMID: 28881918)
N Engl J Med. 2003 Jun 19;348(25):2500-7. (PMID: 12815135)
Thorax. 2007 Aug;62(8):696-701. (PMID: 17687098)
J Nucl Med. 2014 Mar;55(3):373-8. (PMID: 24504054)
Ann Oncol. 2016 Sep;27(suppl 5):v1-v27. (PMID: 27664245)
Invest Radiol. 2008 May;43(5):290-7. (PMID: 18424949)
Radiology. 2003 Nov;229(2):526-33. (PMID: 14512512)
Eur J Cancer. 2013 May;49(8):1860-7. (PMID: 23481511)
Lung Cancer. 2004 Jul;45(1):19-27. (PMID: 15196730)
Clin Nucl Med. 2017 Mar;42(3):180-186. (PMID: 28033217)
Radiology. 2011 Nov;261(2):605-15. (PMID: 21926377)
Radiology. 2008 Aug;248(2):632-42. (PMID: 18552311)
Radiology. 2008 Feb;246(2):596-604. (PMID: 18056854)
J Clin Oncol. 2006 Oct 1;24(28):4539-44. (PMID: 17008692)
Ann Surg Oncol. 2010 Jun;17(6):1471-4. (PMID: 20180029)
J Nucl Med. 2016 Apr;57(4):582-6. (PMID: 26742715)
Ann Thorac Surg. 2000 Oct;70(4):1154-9; discussion 1159-60. (PMID: 11081861)
Eur Radiol. 2017 Feb;27(2):681-688. (PMID: 27180186)
J Nucl Med. 2012 Jun;53(6):928-38. (PMID: 22582048)
Respiration. 2003 Sep-Oct;70(5):500-6. (PMID: 14665776)
J Magn Reson Imaging. 2017 Nov;46(5):1247-1262. (PMID: 28370695)
Eur J Radiol. 2013 May;82(5):870-6. (PMID: 23394765)
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):49-55. (PMID: 25120040)
AJR Am J Roentgenol. 1985 Feb;144(2):261-5. (PMID: 3871268)
J Nucl Med. 2016 Jan;57(1):15-20. (PMID: 26514173)
AJR Am J Roentgenol. 2004 May;182(5):1129-32. (PMID: 15100107)
CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787)
Respirology. 2018 Jan;23(1):76-81. (PMID: 28857362)

Keywords: NSCLC; PET/CT; PET/MRI; Thoracic staging

0Z5B2CJX4D (Fluorodeoxyglucose F18)

Date Created: 20180804 Date Completed: 20190507 Latest Revision: 20200309

20240104

10.1007/s00259-018-4109-x

30074073